Table 1.

Recommendations for the Care of Cancer Survivors*

Table 2.

General Symptoms of Cancer Survivors (Not Related to Specific Cancer or Treatment)

Table 3.

Symptoms Most Common After Treatment of Rectal Cancer*

Rowland JH. What are cancer survivors telling us? Cancer J 2008;14:361-368.
Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2008. CA Cancer J Clin 2008;58:71-96.
Rim SR, Seeff L, Ahmed F, et al. Colorectal cancer incidence in the United States, 1999-2004. Cancer 2009;115:1967-1976.
Edwards BK, Howe HL, Ries LAG, et al. Annual Report to the Nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden. Cancer 2002;94:2766-2792.
Jemal A, Clegg LX, Ward E, et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 2004;101:3-27.
Moertel C, Fleming T, Macdonald J, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322:352-358.
de Gramont A, Boni C, Navarro M, et al. Oxaliplatin/5FU/LV in adjuvant colon cancer: updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years [abstract]. J Clin Oncol 2007;25(Suppl 18S):Abstract 4007.
Krook J, Moertel C, Gunderson L, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991;324:709-715.
Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731-1740.
Hewitt M, Greenfield S, Stovall E. From cancer patient to cancer survivor: lost in transition. Washington, D.C.: The National Academies Press; 2006.
Wilson IB, Cleary PD. Linking clinical variable with health-related quality of life. A conceptual model of patients outcomes. JAMA 1995;273:59-65.
Baker F, Haffer SC, Denniston M, et al. Health-related quality of life of cancer and noncancer patients in Medicare managed care. Cancer 2003;97:674-681.
Baker F, Denniston M, Smith T, West MM. Adult cancer survivors: how are they faring? Cancer 2005;104(Suppl 11):2565-2576.
Lynch BM, Steginga SK, Hawkes AL, et al. Describing and predicting psychological distress after colorectal cancer. Cancer 2008;112:1363-1370.
Stein KD, Syrjala KL, Andrykowski MA, et al. Physical and psychological long-term and late effects of cancer. Cancer 2008;112(Suppl 11):2577-2592.
de Boer AG, Taskila T, Ojajarvi A, et al. Cancer survivors and unemployment: a meta-analysis and meta-regression. JAMA 2009;301:753-762.
Hewitt M, Rowland JH, Yancik R, et al. Cancer survivors in the United States: age, health, and disability. J Gerontol A Biol Sci Med Sci 2003;58:82-91.
Ramsey SD, Berry K, Moinpour C, et al. Quality of life in long term survivors of colorectal cancer. Am J Gastroenterol 2002;97:1228-1234.
Sweeney C, Schmitz KH, Lazovich D, et al. Functional limitations in elderly female cancer survivors. J Natl Cancer Inst 2006;98:521-529.
Deimling GT, Sterns S, Bowman KF, Kahana B. Functioning and activity participation restrictions among older adult, long-term cancer survivors. Cancer Invest 2007;25:106-116.
Given CW, Given B, Azzouz F, et al. Comparison of changes in physical functioning of elderly patients with new diagnoses of cancer. Med Care 2000;38:482-493.
Given BA, Given C, Azzouz F, Stommel M. Physical functioning of elderly cancer patients prior to diagnosis and following initial treatment. Nurs Res 2001;50:222-232.
Deimling GT, Bowman KF, Wagner LJ, et al. The effects of cancer-related pain and fatigue on functioning of older adult, long-term cancer survivors. Cancer Nurs 2007;30:421-433.
Kurtz ME, Kurtz JC, Stommel M, et al. Predictors of depressive symptomatology of geriatric patients with colorectal cancer: a longitudinal view. Support Care Cancer 2002;10:494-501.
Robb C, Haley WE, Balducci L, et al. Impact of breast cancer survivorship on quality of life in older women. Crit Rev Oncol Hematol 2007;62:84-91.
Hewitt M, Rowland JH, Hewitt M, Rowland JH. Mental health service use among adult cancer survivors: analyses of the National Health Interview Survey. J Clin Oncol 2002;20:4581-4590.
Mullens AB, McCaul KD, Erickson SC, et al. Coping after cancer: risk perceptions, worry, and health behaviors among colorectal cancer survivors. Psychooncology 2004;13:367-376.
Deimling GT, Sterns S, Bowman KF, Kahana B. The health of older-adult, long-term cancer survivors. Cancer Nurs 2005;28:415-424.
Deimling GT, Wagner LJ, Bowman KF, et al. Coping among older-adult, long-term cancer survivors. Psychooncology 2006;15:143-159.
Stommel M, Kurtz ME, Kurtz JC, et al. A longitudinal analysis of the course of depressive symptomatology in geriatric patients with cancer of the breast, colon, lung, or prostate. Health Psychol 2004;23:564-573.
Ramsey SD, Andersen MR, Etzioni R, et al. Quality of life in survivors of colorectal carcinoma. Cancer 2000;88:1294-1303.
Schneider EC, Malin JL, Kahn KL, et al. Surviving colorectal cancer: patient-reported symptoms 4 years after diagnosis. Cancer 2007;110:2075-2082.
Trentham-Dietz A, Remington PL, Moinpour CM, et al. Health-related quality of life in female long-term colorectal cancer survivors. Oncologist 2003;8:342-349.
Sapp AL, Trentham-Dietz A, Newcomb PA, et al. Social networks and quality of life among female long-term colorectal cancer survivors. Cancer 2003;98:1749-1758.
Holland JC, Andersen B, Breitbart WS, et al. NCCN Clinical Practice Guidelines in Oncology: Distress Management. Version 2, 2009. Available at: http://www.nccn.org/professionals/physician_gls/PDF/distress.pdf. Accessed July 16, 2009.
Allal AS, Gervaz P, Gertsch P, et al. Assessment of quality of life in patients with rectal cancer treated by preoperative radiotherapy: a longitudinal prospective study. Int J Radiat Oncol Biol Phys 2005;61:1129-1135.
Sideris L, Zenasni F, Vernerey D, et al. Quality of life of patients operated on for low rectal cancer: impact of the type of surgery and patients' characteristics. Dis Colon Rectum 2005;48:2180-2191.
Guren MG, Eriksen MT, Wiig JN, et al. Quality of life and functional outcome following anterior or abdominoperineal resection for rectal cancer. Eur J Surg Oncol 2005;31:735-742.
Arndt V, Merx H, Stegmaier C, et al. Quality of life in patients with colorectal cancer 1 year after diagnosis compared with the general population: a population-based study. J Clin Oncol 2004;22:4829-4836.
Rauch P, Miny J, Conroy T, et al. Quality of life among disease-free survivors of rectal cancer. J Clin Oncol 2004;22:354-360.
Peeters KC, van de Velde CJ, Leer JW, et al. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients—a Dutch Colorectal Cancer Group Study. J Clin Oncol 2005;23:6199-6206.
Cersosimo RJ. Oxaliplatin-associated neuropathy: a review. Ann Pharmacother 2005;39:128-135.
Grothey A. Oxaliplatin-safety profile: neurotoxicity. Semin Oncol 2003;30:5-13.
Kaley TJ, DeAngelis LM. Therapy of chemotherapy-induced peripheral neuropathy. Br J Haematol 2009;145:3-14.
Cavaletti G, Petruccioli MG, Marmiroli P, et al. Circulating nerve growth factor levels changes during oxaliplatin treatment-induced neurotoxicity in the rat. Anticancer Res 2002;22:4199-4204.
Gamelin L, Capitain O, Morel A, et al. Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway. Clin Cancer Res 2007;13:6359-6368.
Grolleau F, Gamelin L, Boisdron-Celle M, et al. A Possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 2001;85:2293-2297.
Park SB, Goldstein D, Lin CS, et al. Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. J Clin Oncol 2009;27:1243-1249.
Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-2351.
Kuebler JP, Wieand S, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007;25:2198-2204.
Land SR, Kopec JA, Cecchini RS, et al. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol 2007;25:2205-2211.
Yothers G, Land SR, Ganz PA, et al. Neurotoxicity (NT) in colon cancer (CC) survivors from NSABP protocol C-07 comparing 5-FU + leucovorin (FULV) with the same regimen + oxaliplatin (FLOX): preliminary results from NSABP protocol LTS-01 [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 9575.
Wang WS, Lin JK, Lin TC, et al. Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients. Oncologist 2007;12:312-319.
Cascinu S, Catalano V, Cordella L, et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2002;20:3478-3483.
Gedlicka C, Scheithauer W, Schull B, Kornek GV. Effective treatment of oxaliplatin-induced cumulative polyneuropathy with alpha-lipoic acid. J Clin Oncol 2002;20:3359-3361.
Argyriou AA, Chroni E, Polychronopoulos P, et al. Efficacy of oxcarbazepine for porphylaxis against cumulative oxaliplatin-induced neuropathy. Neurology 2006;67:2253-2255.
Mitchell P, Goldstein D, Michael M, et al. Addition of gabapentin to a modified folfox regimen does not reduce oxaliplatin-induced neurotoxicity. Clin Colorectal Cancer 2006;6:146-151.
von Delius S, Eckel F, Wagenpfeil S, et al. Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: final results of a randomised, controlled, multicenter phase II study. Invest New Drugs 2007;25:173-180.
Gamelin L, Boisdron-Celle M, Delva R, et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 2004;10:4055-4061.
Hochster HS, Grothey A, Shpilsky A, Childs BH. Effect of intravenous (IV) calcium and magnesium (Ca/Mg) versus placebo on response to FOLFOX+bevacizumab (BEV) in the CONcePT trial. Presented at the ASCO 2008 Gastrointestinal Cancers Symposium; Orlando, Florida; January 25-27, 2008.
Nikcevich DA, Grothey A, Sloan JA, et al. Effect of intravenous calcium and magnesium (IV CaMg) on oxaliplatin-induced sensory neurotoxicity (sNT) in adjuvant colon cancer: results of the phase III placebo-controlled, double-blind NCCTG trial N04C7 [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 4009.
Hochster HS, Grothey A, Childs BH. Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. J Clin Oncol 2007;25:4028-4029.
Gami B, Harrington K, Blake P, et al. How patients manage gastrointestinal symptoms after pelvic radiotherapy. Aliment Pharmacol Ther 2003;18:987-994.
DeSnoo L, Faithfull S. A qualitative study of anterior resection syndrome: the experiences of cancer survivors who have undergone resection surgery. Eur J Cancer Care (Engl) 2006;15:244-251.
Birgisson H, PÃ¥hlman L, Gunnarsson U, Glimelius B. Late gastrointestinal disorders after rectal cancer surgery with and without preoperative radiation therapy. Br J Surg 2008;95:206-213.
Dahlberg M, Glimelius B, Graf W, PÃ¥hlman L. Preoperative irradiation affects functional results after surgery for rectal cancer. Dis Colon Rectum 1998;41:543-549.
Hassan I, Larson D, Cima R, et al. Long-term functional and quality of life outcomes after coloanal anastomosis for distal rectal cancer. Dis Colon Rectum 2006;49:1266-1274.
Kollmorgen CF, Meagher AP, Wolff BG, et al. The long-term effect of adjuvant postoperative chemoradiotherapy for rectal carcinoma on bowel function. Ann Surg 1994;220:676-682.
Lundby L, Krogh K, Jensen VJ, et al. Long-term anorectal dysfunction after postoperative radiotherapy for rectal cancer. Dis Colon Rectum 2005;48:1343-1352.
McGough C, Baldwin C, Frost G, Andreyev HJ. Role of nutritional intervention in patients treated with radiotherapy for pelvic malignancy. Br J Cancer 2004;90:2278-2287.
Andreyev J. Gastrointestinal complications of pelvic radiotherapy: are they of any importance? Gut 2005;54:1051-1054.
Baxter NN, Habermann EB, Tepper JE, et al. Risk of pelvic fractures in older women following pelvic irradiation. JAMA 2005;294:2587-2593.
Small W Jr, Kachnic L. Postradiotherapy pelvic fractures: cause for concern or opportunity for future research? JAMA 2005;294:2635-2637.
Lange MM, Maas CP, Marijnen CA, et al. Urinary dysfunction after rectal cancer treatment is mainly caused by surgery. Br J Surg 2008;95:1020-1028.
Lange MM, Marijnen CA, Maas CP, et al. Risk factors for sexual dysfunction after rectal cancer treatment. Eur J Cancer 2009;45:1578-1588.
Pollack J, Holm T, Cedermark B, et al. Late adverse effects of short-course preoperative radiotherapy in rectal cancer. Br J Surg 2006;93:1519-1525.
Mannaerts GH, Schijven MP, Hendrikx A, et al. Urologic and sexual morbidity following multimodality treatment for locally advanced primary and locally recurrent rectal cancer. Eur J Surg Oncol 2001;27:265-272.
Havenga K, Enker WE, McDermott K, et al. Male and female sexual and urinary function after total mesorectal excision with autonomic nerve preservation for carcinoma of the rectum. J Am Coll Surg 1996;182:495-502.
Wolf JK. Prevention and treatment of vaginal stenosis resulting from pelvic radiation therapy. Community Oncology 2006;3:665-671.
Lindsey I, George B, Kettlewell M, Mortensen N. Randomized, double-blind, placebo-controlled trial of sildenafil (Viagra) for erectile dysfunction after rectal excision for cancer and inflammatory bowel disease. Dis Colon Rectum 2002;45:727-732.
Decruze SB, Guthrie D, Magnani R. Prevention of vaginal stenosis in patients following vaginal brachytherapy. Clin Oncol 1999;11:46-48.
Brown JK, Byers T, Doyle C, et al. Nutrition and physical activity during and after cancer treatment: an American Cancer Society guide for informed choices. CA Cancer J Clin 2003;53:268-291.
Demark-Wahnefried W, Aziz NM, Rowland JH, Pinto BM. Riding the crest of the teachable moment: promoting long-term health after the diagnosis of cancer. J Clin Oncol 2005;23:5814-5830.
Blanchard CM, Courneya KS, Stein K. Cancer survivors' adherence to lifestyle behavior recommendations and associations with health-related quality of life: results from the American Cancer Society's SCS-II. J Clin Oncol 2008;26:2198-2204.
Jones LW, Courneya KS, Fairey AS. Effects of an oncologist's recommendation to exercise on self-reported exercise behavior in newly diagnosed breast cancer survivors: a single-blind, randomized controlled trial. Ann Behav Med 2004;28:105-113.
Meyerhardt JA, Heseltine D, Niedzwiecki D, et al. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol 2006;24:3535-3541.
Meyerhardt JA, Giovannucci EL, Holmes MD, et al. Physical activity and survival after colorectal cancer diagnosis. J Clin Oncol 2006;24:3527-3534.
Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-1638.
Meyerhardt JA, Catalano PJ, Haller DG, et al. Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. Cancer 2003;98:484-495.
Dignam JJ, Polite BN, Yothers G, et al. Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. J Natl Cancer Inst 2006;98:1647-1654.
Meyerhardt JA, Niedzwiecki D, Hollis D, et al. Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803. J Clin Oncol 2008;26:4109-4115.
Meyerhardt JA, Tepper JE, Niedzwiecki D, et al. Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114. J Clin Oncol 2004;22:648-657.
Moon H, Ju Y, Jeong C, et al. Visceral obesity may affect oncologic outcome in patients with colorectal cancer. Ann Surg Oncol 2008;15:1918-1922.
Meyerhardt JA, Niedzwiecki D, Hollis D, et al. Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. JAMA 2007;298:754-764.
Fuchs C, Meyerhardt JA, Heseltine DL, et al. Influence of regular aspirin use on survival for patients with stage III colon cancer: findings from Intergroup trial CALGB 89803 [abstract]. J Clin Oncol 2005;23(Suppl 1):Abstract 3530.
Ng K, Meyerhardt JA, Wu K, et al. Circulating 25-hydroxyvitamin D levels and survival in patients with colorectal cancer. J Clin Oncol 2008;26:2984-2991.
Jackson NA, Fuchs CS, Niedzwiecki D, et al. The impact of smoking on cancer recurrence and survival in patients with stage III colon cancer: findings from Intergroup trial CALGB 89803 [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 4039.
Sargent DJ, Patiyil S, Yothers G, et al. End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT group. J Clin Oncol 2007;25:4569-4574.
Sargent D, Sobrero A, Grothey A, et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2009;27:872-877.
Earle CC, Neville BA. Under use of necessary care among cancer survivors. Cancer 2004;101:1712-1719.
Snyder CF, Earle CC, Herbert RJ, et al. Preventive care for colorectal cancer survivors: a 5-year longitudinal study. J Clin Oncol 2008;26:1073-1079.
Haggstrom D, Arora N, Oakley-Girvan I. Primary and subspecialty care models of follow-up care delivery among colorectal cancer survivors [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 6540.
Snyder C, Earle C, Herbert R, et al. Trends in follow-up and preventive care for colorectal cancer survivors. J Gen Intern Med 2008;23:254-259.
Nissen MJ, Beran MS, Lee MW, et al. Views of primary care physicians on follow-up care of cancer patients. Fam Med 2007;39:477-482.
Sabatino SA, Coates RJ, Uhler RJ, et al. Provider counseling about health behaviors among cancer survivors in the United States. J Clin Oncol 2007;25:2100-2106.
Oeffinger KC, McCabe MS. Models for delivering survivorship care. J Clin Oncol 2006;24:5117-5124.
Earle CC. Failing to plan is planning to fail: improving the quality of care with survivorship care plans. J Clin Oncol 2006;24:5112-5116.
Berger AM, Abernethy AP, Atkinson A, et al. NCCN Clinical Practice Guidelines in Oncology: Cancer-Related Fatigue. Version 1, 2009. Available at: http://www.nccn.org/professionals/physician_gls/PDF/fatigue.pdf. Accessed July 16, 2009.
Mitchell SA, Beck SL, Hood LE, et al. Putting evidence into practice: evidence-based interventions for fatigue during and following cancer and its treatment. Clin J Oncol Nurs 2007;11:99-113.
Page MS, Berger AM, Johnson LB. Putting evidence into practice: evidence-based interventions for sleep-wake disturbances. Clin J Oncol Nurs 2006;10:753-767.

As an organization accredited by the ACCME, MedscapeCME requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

MedscapeCME encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Author(s)

Crystal S. Denlinger, MD

Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania

Disclosures

Disclosure: Crystal S. Denlinger, MD, has disclosed that she has received research funding from Merrimack Pharmaceuticals for phase 1 clinical trials and from Genentech, Inc. for unrelated clinical trials.

Andrea M. Barsevick, RN, PhD

Department of Nursing, Fox Chase Cancer Center, Philadelphia, Pennsylvania

Disclosures

Disclosure: Andrea M. Barsevick, RN, PhD, has disclosed no relevant financial relationships.

Editor(s)

Kerrin G. Robinson, MA

Medical/Scientific Editor, Journal of the National Comprehensive Cancer Network

Disclosures

Disclosure: Kerrin G. Robinson, MA, has disclosed no relevant financial relationships.

CME Author(s)

Charles P. Vega, MD, FAAFP

Associate Professor; Residency Director, Department of Family Medicine, University of California, Irvine

Disclosures

Disclosure: Charles P. Vega, MD, FAAFP, has disclosed no relevant financial relationships.

CME

The Challenges of Colorectal Cancer Survivorship

Authors: Crystal S. Denlinger, MD; Andrea M. Barsevick, RN, PhD
CME Released: 9/21/2009
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 9/21/2010, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This activity is intended for primary care physicians, gastroenterologists, surgeons, radiation oncologists, and other physicians who care for patients with a history of colorectal cancer.

The goal of this activity is to describe common symptoms among survivors of colorectal cancer and the management of these patients.

Upon completion of this activity, participants will be able to:

Analyze the prognosis of colorectal cancer (CRC)
Identify the most common symptom among survivors of CRC
Distinguish emotional concerns among survivors of CRC
Describe long-term symptoms related to the treatment of CRC

Disclosures

Author(s)

Crystal S. Denlinger, MD

Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania

Disclosures

Disclosure: Crystal S. Denlinger, MD, has disclosed that she has received research funding from Merrimack Pharmaceuticals for phase 1 clinical trials and from Genentech, Inc. for unrelated clinical trials.

Andrea M. Barsevick, RN, PhD

Department of Nursing, Fox Chase Cancer Center, Philadelphia, Pennsylvania

Disclosures

Disclosure: Andrea M. Barsevick, RN, PhD, has disclosed no relevant financial relationships.

Editor(s)

Kerrin G. Robinson, MA

Medical/Scientific Editor, Journal of the National Comprehensive Cancer Network

Disclosures

Disclosure: Kerrin G. Robinson, MA, has disclosed no relevant financial relationships.

CME Author(s)

Charles P. Vega, MD, FAAFP

Associate Professor; Residency Director, Department of Family Medicine, University of California, Irvine

Disclosures

Disclosure: Charles P. Vega, MD, FAAFP, has disclosed no relevant financial relationships.

Accreditation Statements

For Physicians

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of MedscapeCME and JNCCN - The Journal of the National Comprehensive Cancer Network.

MedscapeCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

MedscapeCME designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™ . Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. MedscapeCME encourages you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

processing....

Conclusions

Survivorship is a distinct phase of CRC treatment. Goals of care include surveillance for recurrence, management of late and long-term toxicities associated with multimodality treatment, encouragement of healthy diet and lifestyle behaviors, and adherence to recommended preventive care guidelines. Coordination of care, including the use of a survivorship care plan, is paramount to ensuring longevity. Further research evaluating issues specific to CRC survivorship and potential interventions must be a priority.

« Back

Page 6 of 6

CME Information

References

References

Acknowledgments

We would like to thank Drs. Yu-Ning Wong, Roger Cohen, and Paul Engstrom for guidance, review, and editorial comments in the preparation of this manuscript.

Reprint Address

Crystal S. Denlinger, MD, Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111; E-mail: [email protected]

Table 1.

Table 2.

Table 3.

CME

The Challenges of Colorectal Cancer Survivorship

Target Audience and Goal Statement

Disclosures

Author(s)

Crystal S. Denlinger, MD

Andrea M. Barsevick, RN, PhD

Editor(s)

Kerrin G. Robinson, MA

CME Author(s)

Charles P. Vega, MD, FAAFP

Accreditation Statements

For Physicians

Instructions for Participation and Credit

The Challenges of Colorectal Cancer Survivorship: Conclusions

Conclusions

Table of Contents

Acknowledgments

Reprint Address

Table 1.

Table 2.

Table 3.

References

Faculty and Disclosures

Author(s)

Crystal S. Denlinger, MD

Andrea M. Barsevick, RN, PhD

Editor(s)

Kerrin G. Robinson, MA

CME Author(s)

Charles P. Vega, MD, FAAFP

CME

The Challenges of Colorectal Cancer Survivorship

Target Audience and Goal Statement

Disclosures

Author(s)

Crystal S. Denlinger, MD

Andrea M. Barsevick, RN, PhD

Editor(s)

Kerrin G. Robinson, MA

CME Author(s)

Charles P. Vega, MD, FAAFP

Accreditation Statements

For Physicians

Instructions for Participation and Credit

The Challenges of Colorectal Cancer Survivorship: Conclusions

Conclusions

Table of Contents

Acknowledgments

Reprint Address